Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Jun 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system interacts with pancreatic cancer as the disease develops and changes over time. Researchers want to create a detailed "immune map" to better understand how the body’s defenses respond to pancreatic tumors, how these responses change before and after treatment, and how the cancer might avoid being attacked by the immune system. By collecting and analyzing lots of patient information, including medical images and blood samples, the study aims to develop a smart tool using artificial intelligence (AI) that can help diagnose pancreatic cancer early and more accurately. This could also help doctors understand why some treatments work better than others and how the cancer resists certain drugs.

People who may join this study include those with a confirmed diagnosis of primary pancreatic cancer, patients with benign (non-cancerous) pancreatic tumors, individuals with a specific type of pancreatic cyst called IPMN, and healthy volunteers without liver, gallbladder, or pancreas problems. Participants will be asked to provide clinical information, imaging, and blood samples over time to help build this immune map. The study excludes individuals with autoimmune diseases, other active cancers, recent infections, or those taking certain medications that affect the immune system. By taking part, patients can contribute to important research that could lead to better ways to detect and treat pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases
• • Primary PDAC
• • Patients with benign pancreatic tumors
• • IPMN patients diagnosed by pathology/imaging
• Exclusion Criteria:
• • Having autoimmune diseases
• • Accompanied by other malignant tumors
• • History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years)
• • Acute infection
• • History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks
• • Organ decompensation dysfunction
• • Immunodeficiency syndrome
• • Hematological precancerous lesions
• • Accept immunosuppressive therapy
• • Diagnosed coagulation disease